Bristol's Opdivo Delivers, But CheckMate 227 Uncertainties Cloud Quarter

The use of the emerging tumor mutation burden biomarker and its relevance to the outcome of the CheckMate 227 study of Opdivo/Yervoy in first-line lung cancer was a hot topic during Bristol's Q3 earnings call, but questions remain.